Advancements in genetic profiling have led to the growth of targeted therapies, such as FLT3 inhibitors (e.g., midostaurin, gilteritinib) and IDH inhibitors (e.g., ivosidenib, enasidenib), which have shown efficacy in treating AML with specific mutations [5,6]. The gene discussed is IDH2; the disease is acute myeloid leukemia.